4E-BP, eukaryotic initiation factor 4E-binding protein; Akt, Ak thymoma; AML, acute myeloid leukemia; Bcl-2, B-cell lymphoma-2; Bcr-Abl, breakpoint cluster region-abelson; CDK, cyclin-dependent kinase; eIF, eukaryotic initiation factor; ERK, extracellular-signal-regulated kinase; FAB, French-American-British classification system; FACS, fluorescence-activated cell sorting; FITC, fluorescein isothiocynate; FLT3, feline McDonough sarcoma-like tyrosine kinase-3; GI 50 , 50% growth inhibitory concentration; ITD, internal tandem duplications; MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia-1; Mnk, mitogen-activated protein kinase-interacting kinase; mTOR, mammalian target of rapamycin; PARP, poly(ADP-ribose)polymerase; PI, propidium iodide; PI3K, phosphatidylinositol 3-kinase; Pim-1, provirus integration site for Moloney murine leukemia virus-1; Raf, rapidly accelerated fibrosarcoma; Ras, rat sarcoma; Rb, retinoblastoma protein; RNA, ribonucleic acid; rpS6, ribosomal protein; SD, standard deviation; Tb, terbium; WT, wild-type This article has not been copyedited and formatted. The final version may differ from this version. Mnk2 can result in a more pronounced cellular response than targeting Mnk2 alone. MNKI-85, a first-in-class inhibitor of Mnk2, however, can be used as a powerful pharmacologic tool in studying the Mnk2/eIF4E-mediated tumorigenic mechanism. In conclusion, this study provides a better understanding of the mechanism underlying the inhibition of AML cell growth by Mnk inhibitors and suggests their potential utility as a therapeutic agent for AML.
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5 for normal cell growth (Ueda et al., 2004) , the oncogenic activity of Mnk-driven eIF4E has shown to be vital for the proliferation and survival of cancer cells (Topisirovic et al., 2004; Wendel et al., 2007) . Therefore, therapeutic targeting of the Mnk offers an opportunity for the treatment of cancer.
Mnks belong to a serine/threonine kinases family, which were identified as unique interacting proteins for ERK and p38 kinases in the MAPK cascade (Roux and Blenis, 2004; Waskiewicz et al., 1997) . Two Mnk human genes have identified, expressing Mnk1 and Mnk2 proteins which are ~72% identical in their amino acid sequence (Slentz-Kesler et al., 2000) . Alternative splicing in the two Mnk genes further revealed the existence of four isoforms: Mnk1a, Mnk1b, Mnk2a and Mnk2b (Scheper et al., 2003; Waskiewicz et al., 1997) .
Bearing a nuclear localization signal and a polybasic sequence in the common basic Nterminal stretch; all four isoforms preferentially localize in the nucleus and phosphorylate eIF4E efficiently.
The difference between the four isoforms arises from the C-termini, in which only the aisoforms have a MAPK-binding site for interaction with ERK or p38 kinases (Parra et al., 2005) . Despite this, Mnk1a and Mnk2a differ in basal activity as shown in in vitro studies ). Activation of ERK or p38 kinase could result in marked increase in the activation of the low basal activity of Mnk1a but negligibly influence the high basal activity of Mnk2a. Both Mnk1a and Mnk2a bind preferentially to ERK but only Mnk1a is a substrate for p38. In appreciation of the dissimilarity in the regulatory features of Mnk1 and Mnk2, these findings may indicate differences in activity and regulation of Mnks towards eIF4G to phosphorylate eIF4E.
An increasing body of evidence has demonstrated the potential anti-leukemic properties of pharmacologic Mnk inhibitors (Altman et al., 2013; Diab et al., 2014b; Lim et al., 2013) . This article has not been copyedited and formatted. The final version may differ from this version. Cercosporamide, a non-selective Mnk inhibitor (Konicek et al., 2011) , reduces leukemic cell proliferation in MM6, K562 and U937 cell lines in a dose-dependent manner (Altman et al., 2013) . The antitumor efficacy of cercosporamide in MV4-11 xenografts supports its Mnktargeted anti-leukemic effects. The cell-specific effect, predominantly in leukemia cells, of Mnk inhibition, have been recently confirmed by our recent discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazole-2(3H)-one Mnk inhibitors (Diab et al., 2014b) .
We have recently identified thieno [2,3-d] 
Materials and Methods

Inhibitor compounds and proteins
Syntheses of MNKI-19 and MNKI-85 were described below. The Mnk inhibitor N 3 -(4-fluorophenyl)-1H-pyrazolo- [3,4-d] pyrimidine-3,4-diamine (CGP57380) was purchased from
Sigma Aldrich, and used as a positive control. All compounds used were dissolved in dimethylsulfoxide (DMSO) at a stock concentration of 10 mM, and stored at -20 °C in small aliquots. eIF4E-derived peptides, TAMRA-DTATKSGSTTKNR, TAMRAThis article has not been copyedited and formatted. The final version may differ from this version. and ionization of all samples was carried out using ESI. Melting points were determined using an open capillary on a Stuart SMP10 melting point apparatus and are uncorrected. The purity of compounds used for biological evaluation was determined by analytic RP-HPLC which was carried out on a Shimadzu Prominence UFLC system (UltraFast Liquid Chromatograph, Kyoto, Japan) equipped with a CBM-20A communications bus module, a DGU-20A5R degassing unit, an LC-20AD liquid chromatograph pump, an SIL-20AHT autosampler, an SPD-M20A photo diode array detector, a CTO-20A column oven and a Phenomenex Kinetex 5u C18 100A 250 mm × 4.60 mm column. Method A (gradient 5% to 95% CH 3 OH containing 0.1% formic acid (FA) over 7 min at a flow rate of 1 mL/min, followed by 95% CH 3 OH containing 0.1% FA over 13 min) and method B (gradient 5% to 95% CH 3 CN containing 0.1% FA over 7 min at a flow rate of 1 mL/min, followed by 95%
This article has not been copyedited and formatted. The final version may differ from this version. (Cheng and Prusoff, 1973) . For kinase panel screen, the kinase activities were reported as remaining activities that were calculated as percentage relative to the averages of multiply 0 and 100% controls, at a compound concentration of 5 μ M.
IMAP TM TR-FRET Progressive Binding System
Each compound (1 and 10 µM in 0.5% DMSO) was added to the kinase reaction 
ADP-Glo TM Kinase Assay
The ADP-Glo TM assay kits were purchased from Promega (Madison, WI, USA). Serial dilution of compounds with a dilution factor of 1:3 was performed to give 8 concentrations ranging from 10 µM to 4.5 nM with 0.5% DMSO. Each compound was added to the kinase reaction containing 1× kinase reaction buffer, 0.1 mg/mL bovine serum albumin, distilled 
Caspase-3/7 Assay
Activity of caspase-3/7 was measured using the Apo-ONE Homogeneous Caspase-3/7 kit (G7790 Promega, Madison, WI, USA) according to manufacturer instruction and analyzed using an EnVision multi-label plate reader (PerkinElmer, Beaconsfield, Buckinghamshire, UK).
Cell Cycle and Detection of Apoptosis
MOLM-13 and MV4-11 (1 × 10 5 ) cells were seeded and incubated overnight at 37 °C, 5% CO 2 . Cells were centrifuged at 300 × g for 5 min upon treatment with each compound. Cell pellets were collected and fixed with 70% ethanol on ice for 15 min, followed by centrifugation at 300 × g for 5 min. The collected pellets were incubated with staining solution (50 µg/mL propidium iodide (PI), 0.1 mg/mL ribonuclease A, 0.05% Triton X-100) This article has not been copyedited and formatted. The final version may differ from this version. 
Western blots
Western blotting was performed as described previously (Wang et al., 2004 
Statistical Analyses
All experiments were performed in triplicate and repeated at least three times; representative experiments were selected for figures. Statistical significance of differences observed between experimental groups was determined using one-way analysis of variance (ANOVA), with a minimal level of significance at p < 0.05.
Results
MNKI-19 and MNKI-85 are potent and selective Mnk inhibitors
This article has not been copyedited and formatted. The final version may differ from this version. (Wander et al., 2014) . As one of the downstream effectors of FLT3, Pim-1 was inhibited potently by cercosporamide (Konicek et al., 2011) , it is thus of great interest to evaluate the inhibitory activities of the compounds against FLT3 and Pim-1.
The results obtained from in-house IMAP assays for Mnk1 and Mnk2 at 1 µM of the tested compounds were included for comparison. Both compounds are inactive against most of the upstream kinases, with the exception that MNKI-19 displays moderate activity against Pim-1 Table 1 ). However, it is 12-and 35-fold less active when compared to these of Mnk1 and Mnk2, respectively. Collectively, these data suggest the high specificity of MNKI-19 and MNKI-85 for Mnks.
MNKI-19 and MNKI-85 exhibit anti-leukemic activity
The anti-proliferative activity of both MNKI-19 and MNKI-85 were assessed on a panel of six AML cell lines and one CML cell line (Table 2 ) using 72 h resazurin assays. CGP57380
was included as a control. All compounds exhibited the greatest anti-proliferative effects on MOLM-13 and MV4-11, both of which expressed FLT3-ITD (Quentmeier et al., 2003) (Table 2) .
MNKI-19 and MNKI-85 inhibits the phosphorylation of eIF4E and 4E-BP1
We However, little to no effect on the levels of p38 and ERK proteins and their phosphorylated forms was observed after treating MOLM-13 with 20 µM compounds for 24 h ( Figure 2B ).
At 24 h, the complete abolition of p-eIF4E S209 by Mnk inhibitors gave rise to a reduction in the phosphorylation of 4E-BP1 at Thr37/46 ( Figure 2C and Supplemental Figure 1 ) and Thr70 ( Figure 2C ), particularly at the latter in a dose-dependent manner, in MOLM-13 cells.
MNKI-19 and MNKI-85 arrest cancer cells in the G 1 phase of cell cycle via downregulating CDK4 and cyclin D3
We next investigated whether the anti-proliferative activity of MNKI-19 and MNKI-85 was a consequence of cell cycle effects. As shown in Figure 3A , treatment of MOLM-13 cells with MNKI-19 or MNKI-85 at 5 μ M for 24 h resulted in the accumulation of G 1 cells, which was accompanied by a loss in cell population at the G 2 /M phase. This is consistent with previous studies (Diab et al., 2014b; Zhang et al., 2008) . The cell cycle effect of MNKI-19 was found to behave in a dose-and time-dependent manner. Consistently, this was observed with MV4-11 cells after treatment with the compounds ( Figure 3B ). However, in the case of MNKI-85, there was no significant change in the cell cycle distribution observed with longer treatment time. Time-course Western blot analysis was conducted to study the levels of key proteins involved in cell cycle after treatment of MOLM-13 cells with compound inhibitors for 1 h and 24 h. Attempts were made to study the expression level of cyclin D1 in MOLM-13 cells but the protein was too weak to be detected (data not shown), hence cyclin D3 was This article has not been copyedited and formatted. The final version may differ from this version. pursued. In human somatic cells, the G 1 to S phase transition is tightly regulated by the cyclin-D/CDK4/6 proteins, along with their downstream target, retinoblastoma (Rb) protein (Neganova and Lako, 2008) . As shown in Figure 3C , no significant changes were detected in these cell cycle regulators at the early time-point (i.e. 1 h) (see also Supplemental Figure 2 ).
However, 24 h incubation of MOLM-13 cells with Mnk inhibitors resulted in the suppression of cyclin D3 expression in a dose-dependent manner ( Figure 3D ). CDK4 was also downregulated by Mnk inhibitors at low concentration.
To investigate whether the perturbation of cell cycle progression is a consequence of CDK4 activity, the phosphorylation of Rb at both CDK4-specific Thr826 (p-Rb and MNKI-85 have no inhibitory effect on CDK4 kinase activity (Table 1) , implying the decreased CDK4 protein expression is a consequence of the down-regulating Mnk/eIF4E-mediated protein synthesis of cyclin D3. In contrast, little effect on CDK6 or CDK6-specific p-Rb T821 levels was observed ( Figure 3E , Supplemental Figure 4 ), supporting the relative importance of CDK4 over CDK6 in the cell cycle progression (Neganova and Lako, 2008) .
MNKI-19 and MNKI-85 induce apoptosis in FLT3-ITD-expressed AML cells
The apoptotic mechanism of action by Mnk inhibitors was further examined using annexin Figure 4E ), which is in agreement with our previous results obtained using MV4-11 (Diab et al., 2014b) .
In conjunction with no aberration in full length caspase-3 protein levels ( Figure 4E ) and no detectable caspase-3/7 activity ( Figure 4F ), the data indicate that Mnk inhibitor-induced apoptosis in MOLM-13 and MV4-11 cells may be independent of caspases-3 and -7.
Discussion
Screening against a panel of 7 leukemia cell lines with various FLT3 mutational statuses revealed the selective Mnk inhibitors MNKI-19 and MNKI-85 are particularly effective in suppressing the growth of FLT3/ITD-expressing AML cells, including MOLM-13 and MV4-11. PL-21 cells, in contrast, expressing both WT and mutated alleles (Quentmeier et al., 2003) , were less sensitive to these compounds. However, it remains debatable that PL-21 cells could only express the WT allele (Yokota et al., 1997) . Nevertheless, the differences in the sensitivity between the cell lines could be attributed to the different subtypes, which are classified based on the morphology and immunohistochemistry of myeloid neoplasms (Bennett et al., 1985) . Both MOLM-13 and MV4-11 are acute monoblastic leukemia cells (M5/M5a) (Quentmeier et al., 2003) that carry the respective t(9,11) and t(4,11) chromosomal translocations, resulting in the fusion proteins MLL-AF9 and MLL-AF4, respectively
This article has not been copyedited and formatted. The final version may differ from this version. (Andersson et al., 2005; . Of note, these subtypes of AML are correlated with aberrant up-regulation of eIF4E (Topisirovic et al., 2003) , which is absent in the less mature promyelocytic cells (M3; PL-21 cells) (Quentmeier et al., 2003) . As a comparator, THP-1 cells with the t(9,11) chromosomal translocation and no detectable FLT3-ITD expression, exhibited negligible sensitivity to . Similarly, HL-60, U937 and K562, which do not express ITD mutations, have no cytotoxic effects when treated with the compounds for up to 3 days. These results are in agreement with a previous study, in which inhibiting 50% of cell growth in K562, U937 and MM6 cell lines after 5-day treatment also required > 10 µM of cercosporamide (Altman et al., 2013) . CGP57380, on the other hand, is not particularly selective against the ITD-positive cells, indicating an alternative mechanism underlying the growth inhibitory effects. When considered together, concurrently activated upstream signaling pathways of Mnks with overexpressed eIF4E levels as characterized by the combined FLT3-ITD mutations and M5 subtypes, may serve as the right platform for investigation of the anti-leukemic effects of Mnk-specific inhibitors.
Western blot analysis further confirmed the role of MNKI-19 and MNKI-85 as potent Mnk inhibitors, as evidenced by the blockage of eIF4E S209 phosphorylation. As Mnks are important convergence nodes of the MAPK pathways (Chappell et al., 2011; Faivre et al., 2006) , the expression of the upstream effectors, p38 and ERK, was also investigated.
Interestingly, an early transient phosphorylation of ERK and p38 was found to be upregulated upon incubation with MNKI-19 for 1 h, without affecting their total levels. Similar effects were seen in CGP57380-treated cells but not in MNKI-85. This could be attributed to the induction of negative-feedback mechanism upon Mnk1 inhibition as both ERK and p38
are substrates for Mnk1 (Waskiewicz et al., 1997) . Such an observation is consistent to a study done by Zhang et al. who has reported that CGP57380-mediated ERK and Mnk activation was determined at early time-point (i.e. 30 min) and followed by a second late This article has not been copyedited and formatted. The final version may differ from this version. 20 phosphorylation starting at 24 h in the Bcr-Abl-dependent cells (Zhang et al., 2008) . Little to no effect on the levels of ERK and p38 proteins and their phosphorylated forms was observed after treating MOLM-13 with 20 µM compounds for 24 h, supporting that the sustained phosphorylation at late time-point is dependent on the presence of Bcr-Abl and signifying the specific effect of our Mnk inhibitors on Mnk/eIF4E. The compounds were also evaluated against a panel of upstream activating kinases, including B-Raf, ERK, p38α, PI3K, Akt1 and mTOR, using biochemical assays, and showed no significant kinase inhibitory activity, supporting selectivity of the compounds.
Interestingly, down-regulations of the levels of phosphorylated 4E-BP1 at Thr37/46 and Thr70 (the two most priming phosphorylation events for the upstream affector mTOR) (Gingras et al., 2001) were detected in MOLM-13 cells treated with either MNKI-19 or MNKI-85. Binding of eIF4E to 4E-BP1 is regulated by hierarchical multisite phosphorylation and the role of the phosphorylation site at Thr37/46 on eIF4E binding remains controversial:
several studies claimed that the phosphorylation of Thr37/46 has little effect on the binding of eIF4E Karim et al., 2001) , while the other group showed that a significant reduction in eIF4E-binding affinity was induced by such a phosphorylation event (Burnett et al., 1998) . However, mutations of these residues and/or Thr70 to alanine, have significantly led to the dissociation of eIF4E from 4E-BP1 (Gingras et al., 2001) , confirming the important role of these phosphorylation sites on the eIF4E/4E-BP1 equilibrium.
In light of these findings, it is speculated that a negative-feedback regulatory mechanism involving the equilibrium shift towards the eIF4E/4E-BP1 complex could be triggered in the compound-treated cells. Translation processes involve the assembly of several eIF4 translational factors, including the eIF4E and activated Mnks to form the eIF4F complex (Hou et al., 2012) . Inhibition of Mnks, especially Mnk2, may increase the levels of eIF4E in the cells as the formation of eIF4F complex has been disrupted. As the Akt/mTOR pathway is This article has not been copyedited and formatted. The final version may differ from this version. (Hayakawa et al., 2000) , it is suspected that the up-regulated eIF4E levels have initiated the negative-feedback mechanism of Akt/mTOR to dephosphorylate 4E-BP1. Upon hypo-phosphorylation, 4E-BP1 interacts strongly with eIF4E (Khaleghpour et al., 1999) . While our compounds were inactive to the upstream kinases in the Akt/mTOR pathway, particularly mTOR, it is believed that the dephosphorylation events were induced upon Mnk inhibition.
Complementary to this, a recent study used CGP57380 to investigate the effect of eIF4E phosphorylation on translation initiation, showing that the amount of eIF4G in the eIF4F complex was decreased when treated with the compound (Li et al., 2010) . This implies that inhibiting Mnks may reduce the eIF4F assembly. Another recent study also suggested that the dissociation of 4E-BP1 is highly dependent on the Mnk1-mediated eIF4E phosphorylation (Das et al., 2013) . The dephosphorylation of 4E-BP1 by MNKI-19 could be also due to the Pim-1 inhibition as shown in the kinase assay. The 4E-BP1 has recently been identified as a target of Pim-1 in the FLT3-ITD-driven activation of STAT-5. Pim-1 inhibitors have significantly reduced the p-4E-BP1 T37/46 in the FLT3-ITD AML cells (Chen et al., 2011) .
However, more studies on the binding affinity of compounds MNKI-19 and MNKI-85 for the relevant proteins, such as eIF4G and 4E-BP1, are required to unveil the underlying mechanism.
The oncogenic role of eIF4E has been reported in the cell cycle progression (Diab et al., 2014a) . D-type cyclins, as G 1 progression factors, play a vital role in enhancing the G 1 to S transition through binding to the CDK4/6 (Sherr, 1995) . Elevated eIF4E levels have been shown to enhance the translational levels of a wide array of malignancy-related mRNAs involved in the regulation of cell senescence, proliferation and apoptosis, including cyclin D1
and Mcl-1 (Zimmer et al., 2000) , whereas the oncogenic functions of eIF4E are closely linked to its phosphorylation by Mnks (Diab et al., 2014a; Ueda et al., 2010) . Consistent with This article has not been copyedited and formatted. The final version may differ from this version. (Diab et al., 2014b; Teo et al., 2015; Zhang et al., 2008) , Mnk inhibitors in the current study triggered a cell cycle arrest in both MOLM-13 and MV4-11 cells by disrupting the transition of G 1 to S phase. Such an effect is likely to be the result of decreased expression of the key cell cycle regulators, including CDK4 and cyclin D3, which further hampered the phosphorylation of Rb at the CDK4-specific Thr826 site (Macdonald and Dick, 2012) . This is further supported when kinase assays showed both MNKI-19 and MNKI-85 have no effect on CDK4 kinase activity (K i > 10 μ M). Previous studies also demonstrated the importance of cyclin D3 at the translational level over other D-type cyclins (Prabhu et al., 2007; Zhang et al., 2008) .
Collectively, these results indicate that the effect of eIF4E-mediated cell cycle arrest is through phosphorylation by Mnks. While MNKI-19 increased the G 1 cell accumulation in a time-dependent manner, MNKI-85 failed to show the similar cell cycle effect ( Figure 3A and B), suggesting that targeting a combination of Mnk1 and Mnk2 may be more effective than one of the isoforms alone in preventing cell cycle progression. Our observation agrees with a recent study of a series of Mnk degrading agents which showed to induce a G 1 /G 0 cell cycle arrest, along with the down-regulation of cyclin D3 and CDK4 in MDA-MB-231 cells (Ramalingam et al., 2014) .
The apoptotic effect of Mnk inhibitors is likely mediated through the 4E-BP1/eIF4E axis.
Several lines of evidence have indicated the positive correlation between the suppression of eIF4E by binding to 4E-BP1 and induction of apoptosis (Clemens, 2001; Yellen et al., 2013) .
To date, Mnk1 and Mnk2 are the only identified kinases that phosphorylate eIF4E, and phosphorylation of eIF4E modulates cap-dependent translation. In addition, eIF4E
phosphorylation can be down-regulated by 4E-BP1 binding (Li et al., 2010) , this has, hence, raised the possibility that inhibiting Mnks triggers the dephosphorylation of 4E-BP1 and results in the reduction of cap-dependent protein synthesis, including Mcl-1. In contrast, the This article has not been copyedited and formatted. The final version may differ from this version. (Chen et al., 2011) .
We have shown that inhibition of eIF4E phosphorylation with Mnk inhibitors is associated with an increase in cell death. An increase cleavage of PARP and a marked suppression of
Mcl-1 levels were observed. Lack of procaspase-3 processing and caspase-3/7 activation suggest that the apoptotic cell death by Mnk inhibitors may be via a caspase-independent mechanism. In contrast, a recent study demonstrated a caspase-dependent apoptosis was induced with Mnk degrading agents in breast cancer cell lines (Ramalingam et al., 2014 
